Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization

Melanoma Research

Volumn 22, Issue 3, 2012, Pages 202-214

  Lázár, Viktória ^a   Ecsedi, Szilvia ^a   Vízkeleti, Laura ^a   Rákosy, Zsuzsa ^a   Boross, Gábor ^c   Szappanos, Balázs ^c   Bégány, Ágnes ^b   Emri, Gabriella ^b   Ádány, Róza ^a   Balázs, Margit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Medical and Health Science Center   (Hungary)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

Array comparative genomic hybridization; BRAF mutation; NRAS mutation; Primary melanoma; Signaling pathway

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; ONCOPROTEIN; PROTEIN NRAS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 7; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC DIFFERENCE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; CHROMOSOMES, HUMAN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE REGULATORY NETWORKS; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860743139     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328352dbc8     Document Type: Article

References (58)

1. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 2008; 624:89-103.
2. Marugame T, Zhang MJ. Comparison of time trends in melanoma of skin cancer mortality (1990-2006) between countries based on the WHO mortality database. Jpn J Clin Oncol 2011; 40:710.
3. Hollestein LM, van den Akker SA, Nijsten T, Karim-Kos HE, Coebergh JW, de Vries E. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2011; 23:524-530.
4. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179-185. (Pubitemid 38352453)
5. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147. (Pubitemid 41653105)
6. Kabbarah OCL. Revealing the genomic heterogeneity of melanoma. Cancer Cell 2005; 8:439-441.
7. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 2006; 19:40-49.
8. Greshock J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, et al. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer 2009; 48:419-428.
9. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010; 49:733-745.
10. Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringner M, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007; 26:4738-4748. (Pubitemid 47067402)
11. Lazar V, Ecsedi S, Szollosi AG, Toth R, Vizkeleti L, Rakosy Z, et al. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Mod Pathol 2009; 22:1367-1378.
12. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanomayand beyond. Ann Surg Oncol 2010; 17: 1475-1477.
13. Treszl A, Ladanyi A, Rakosy Z, Buczko Z, Adany R, Balazs M. Molecular cytogenetic characterization of a novel cell line established from a superficial spreading melanoma. Front Biosci 2006; 11:1844-1853. (Pubitemid 43256427)
14. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20:207-211. (Pubitemid 28455458)
15. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. Fully automatic quantification of microarray image data. Genome Res 2002; 12:325-332. (Pubitemid 34162999)
16. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, Barok M, et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007; 121:1729-1737. (Pubitemid 47417290)
17. Rakosy Z, Vizkeleti L, Ecsedi S, Begany A, Emri G, Adany R, et al. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 2008; 182:116-121. (Pubitemid 351491330)
18. Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK, Borresen-Dale AL. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 2005; 21:821-822. (Pubitemid 40439420)
19. Lai WR, Johnson MD, Kucherlapati R, Park PJ. Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data. Bioinformatics 2005; 21:3763-3770. (Pubitemid 41535525)
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121. (Pubitemid 32397092)
21. Peter H, Westfall SSY. Resampling-based multiple testing: examples and methods for P value adjustment. New York: John Wiley and Sons 1993.
22. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004; 64:8541-8549. (Pubitemid 39552066)
23. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems 2006; 83:81-90. (Pubitemid 43199809)
24. Stelling J, Sauer U, Szallasi Z, Doyle FJ III, Doyle J. Robustness of cellular functions. Cell 2004; 118:675-685. (Pubitemid 39221728)
25. Korcsmaros T, Farkas IJ, Szalay MS, Rovo P, Fazekas D, Spiro Z, et al. Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery. Bioinformatics 2010; 26:2042-2050.
26. Liaw A.W.M. Classification and regression by randomForest. R News 2002; 2:18-22.
27. Breiman L. Random forests. Machine Learning 2001; 45:5-32. (Pubitemid 32933532)
28. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000; 405:974-978. (Pubitemid 30435057)
29. Bastian B.C., Olshen A.B., Leboit P.E., Pinkel D. Classifying melanocytic tumors based on DNA copy number changes Am J Pathol 2003 163 1765-1770. (Pubitemid 37310008)
30. Wiltshire RN, Dennis A, Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163:1765-1770. (Pubitemid 37310008)
31. Sondak VK, Meltzer PS, Trent JM. Application of molecular cytogenetic techniques in a case study of human cutaneous metastatic melanoma. Cancer Genet Cytogenet 2001; 131:97-103. (Pubitemid 34003057)
32. Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46:222-232. (Pubitemid 32899792)
33. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011; 8:426-433.
34. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-947. (Pubitemid 39626217)
35. Tsuchiya E, Tanigami A, Ishikawa Y, Nishida K, Hayashi M, Tokuchi Y, et al. Three new regions on chromosome 17p13. 3 distal to p53 with possible tumor suppressor gene involvement in lung cancer. Jpn J Cancer Res 2000; 91:589-596. (Pubitemid 30453785)
36. Chattopadhyay P, Rathore A, Mathur M, Sarkar C, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus on 17p13. 3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene 1997; 15:871-874.
37. Parrella P, Scintu M, Prencipe M, Poeta ML, Gallo AP, Rabitti C, et al. HIC1 promoter methylation and 17p13. 3 allelic loss in invasive ductal carcinoma of the breast. Cancer Lett 2005; 222:75-81. (Pubitemid 40544849)
38. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, et al. Allelic deletion on chromosome 17p13. 3 in early ovarian cancer. Cancer Res 1996; 56:606-611. (Pubitemid 26043661)
39. Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13. 3. Cancer Res 1996; 56:1997-2002. (Pubitemid 26119896)
40. Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, Godwin AK. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res 1999; 59:4973-4983. (Pubitemid 29472903)
41. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122:337-341. (Pubitemid 38281053)
42. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003; 22:3113-3122. (Pubitemid 36713763)
43. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008; 68:664-673. (Pubitemid 351206741)
44. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34:337-343. (Pubitemid 36792869)
45. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-152.
46. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011; 128:1758-1769.
47. Aslanian A, Iaquinta PJ, Verona R, Lees JA. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 2004; 18:1413-1422. (Pubitemid 38780628)
48. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331. (Pubitemid 27131374)
49. Tomioka N, Morita K, Kobayashi N, Tada M, Itoh T, Saitoh S, et al. Array comparative genomic hybridization analysis revealed four genomic prognostic biomarkers for primary gastric cancers. Cancer Genet Cytogenet 2010; 201:6-14.
50. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 2009; 129:1500-1515.
51. Diaz-Uriarte R, Alvarez de Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006; 7:3-16.
52. Gunther EC, Stone DJ, Gerwien RW, Bento P, Heyes MP. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc Natl Acad Sci USA 2003; 100:9608-9613. (Pubitemid 37033975)
53. Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 2005; 11: 1146-1153. (Pubitemid 40175764)
54. Mandl M, Slack DN, Keyse SM. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 2005; 25:1830-1845. (Pubitemid 40280148)
55. Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. RNAimediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008; 27:5315-5325.
56. Ahmed SU, Milner J. Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One 2009; 4: e7305-e7318.
57. Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, et al. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol 2007; 171:297-303. (Pubitemid 47339246)
58. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6:880-886. (Pubitemid 30159344)